证券分析师 胡琼方 投资咨询资格编号：S1060524010002 2025年7月2日 请务必阅读正文后免责条款 投资要点 1 新一代消费者成长于互联网及移动互联网时代，同时期我国工业制造业蓬勃发展，商品供应逐步充足、信息不对称性快速消弭。新世代 群体注重体验、主打真实、关注自我、个性化等消费偏好驱动出行、零售、美业和宠物等领域变化。 旅游消费潜力持续释放，关注广谱性受益的OTA平台：①国内游：高层多次会议部署促进服务消费，文旅作为其中重要一环近年来持续恢 复，暑期临近，建议关注出行β行情（景区、酒旅等）。②出境游部分预计会受国际环境变化带来的情绪扰动及安全风险影响，入境游 在我国免签政策及美国顶流网红"甲亢哥"中国行带动China Travel流量之下有望进一步增长。个股层面建议关注广谱性受益的OTA平台 企业携程集团-S、同程旅行。 零售回归消费需求本身：①传统零售：社零不同品类表现分化，粮油食品等刚需品及近年来的情绪、文化消费及国货替代品较高速成长。 物质消费整体进入买方市场阶段，线上及线下零售渠道均在回归消费需求本身，零售商/平台扶持优质品牌和商家、优化商品结构、提升 消费体验。建议关注阿里巴巴、永辉 ...

Investment Rating - The report maintains an "Outperform" rating for the industry [7] Core Insights - The report emphasizes the upcoming summer peak season as a catalyst for the tourism and cultural sectors, highlighting the integration of cultural tourism with IP-driven new consumption logic [2][3] - It suggests focusing on the IP + scenic area concept, particularly in regions like Jiangsu, and recommends companies such as Emei Mountain A, Changbai Mountain, Xiangyuan Cultural Tourism, and Haichang Ocean Park [3][21] - The report notes the stabilization of second-hand prices in the trendy toy sector, driven by the summer season, while also addressing regulatory risks and price fluctuations in the second-hand market [3][22] - In the gold and jewelry sector, the report highlights the potential for high growth in terminal store efficiency and expansion opportunities for brands targeting high-end and young consumers [4][131] - The beauty and personal care sector is identified as having structural opportunities, with a focus on product innovation and long-term growth potential [5][101] Summary by Sections 1. Duty-Free and Scenic Areas - The report tracks the performance of duty-free operators and suggests focusing on city duty-free store openings to capture inbound tourist spending [14] - It highlights the summer tourism market's preparation, with a predicted peak in hotel guest flow in early August [15][21] 2. Trendy Toys - The report notes a significant year-on-year increase in online sales for the trendy toy sector, with a total of approximately 2,754 million yuan in sales from January to May 2025, reflecting a 61% growth [23] - It emphasizes the strong cultural presence of LABUBU, surpassing the popularity of Nintendo Switch2 and LOL in recent trends [3][27] 3. Gold and Jewelry - The report indicates that gold prices remain high, with retail sales in the gold and jewelry sector reaching 30 billion yuan in May 2025, a year-on-year increase of 21.8% [128][131] - It recommends brands like Chaohongji, Laisentongling, and Laopu Gold for their growth potential in high-end markets [131] 4. Beauty and Personal Care - The report identifies significant growth opportunities in the beauty sector driven by product innovation and changing consumer habits, recommending companies like Mao Ge Ping and Shangmei [5][101] - It highlights the successful listing of Ying Tong Holdings as a leading player in the fragrance distribution and brand management sector [68] 5. Medical Aesthetics - The report suggests that the medical aesthetics industry is poised for market share gains due to refined operations and the upcoming release of new products in Q3 [5][61] - It recommends focusing on companies like Jinbo Bio and Sihuan Pharmaceutical for their innovative product pipelines [5][66] 6. Employment and Human Resources - The report notes a stable employment situation with a slight decrease in urban unemployment rates, suggesting a focus on flexible employment leaders [102][105] 7. Sports and Events - The report highlights the ongoing development of outdoor sports and suggests monitoring the "Su Chao" theme for investment opportunities in related companies [111]

数据来源：聚源 -29% -14% 0% 14% 29% 43% 58% 2024-04 2024-08 2024-12 商贸零售 沪深300 相关研究报告 《"美团闪购"品牌独立，即时零售模 式加速发展—行业周报》-2025.4.20 《医美化妆品 3 月月报：锦波生物首 个胶原蛋白填充三类械获批，关注"情 绪消费"主线下的美妆机遇—行业点 评报告》-2025.4.19 《2025 年 3 月社零同比+5.9%，期待 后续消费潜力释放—行业点评报告》 -2025.4.16 年报一季报陆续披露，关注高景气板块优质公司 商贸零售 商贸零售 2025 年 04 月 27 日 投资评级：看好（维持） 行业走势图 ——行业周报 | 黄泽鹏（分析师） | 陈思（联系人） | | --- | --- | | huangzepeng@kysec.cn | chensi@kysec.cn | | 证书编号：S0790519110001 | 证书编号：S0790124070031 | chensi@kysec.cn 证书编号：S0790124070031 年报一季报陆续披露，关注高景气板块优质公司 上市公司陆续披露 2024 ...

Core Viewpoint - The company reported a steady growth in revenue and net profit for 2024 despite industry pressures, with a revenue of 3.03 billion and a net profit of 1.96 billion, reflecting year-on-year increases of 5.4% and 5.3% respectively [2][3] Revenue and Profit Analysis - In Q4 2024, the company's revenue was 650 million, showing a year-on-year decline of 7.0%, while the net profit was 370 million, down 15.5% year-on-year [2] - The revenue from solution products and gel products for 2024 was 1.74 billion and 1.22 billion respectively, with year-on-year growth of 4.4% and 5.0% [3] Product Performance - The sales volume for solution products was 634.6 thousand units, up 23.4% year-on-year, while gel products saw a decline in sales volume to 89.4 thousand units, down 11.2% [3] - The average price of solution products decreased due to a shift in product mix, while the average price of gel products increased due to a higher proportion of high-margin products [3] Profitability Metrics - The company's gross margin for 2024 was 94.6%, a decrease of 0.5 percentage points year-on-year, while the net profit margin was 64.7%, down 0.1 percentage points [4] - In Q4 2024, the gross margin was 94.0%, down 0.4 percentage points year-on-year, and the net profit margin was 57.2%, down 5.7 percentage points [4] R&D and Cost Management - The company increased its R&D investment, with a R&D expense ratio significantly rising, completing 57 patent applications and engaging in 21 collaborative research projects with medical institutions [4] - The overall expense ratio increased by 1.3 percentage points to 22.2%, driven by higher R&D costs, while sales expenses remained stable [4] Product Line Expansion - The company received a Class III medical device registration for a new gel product, expected to launch this year, which will enhance its gel product line [5] - Clinical trial approvals were obtained for several new products, indicating ongoing innovation and product development [5] Strategic Acquisition - The company plans to acquire REGEN Biotech, Inc. in March 2025, which is expected to strengthen its competitive advantage in the global regenerative market and enhance its overseas market expansion capabilities [7]

报告摘要 事件： 点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 AestheFill作为国内首款获批的进口童颜针，此前江苏吴中曾通过收购达透医疗取得了其在中国大陆的独家 代理权，并于2024年4月正式上市销售，在国内医美市场反响热烈。此次收购完成后，爱美客将在现有濡 白天使、如生天使的基础上进一步完善其再生医美产品体系，有利于技术融合和产品协同，提升高端产品 收入占比。 双向协同，助力公司开拓海外市场 REGEN Biotech, Inc.公司的AestheFill已获得了包括34个国家和地区的注册批准，并建立了广泛的分销体 系，在除中国大陆以外的中国台湾、韩国等多地医美市场占据一定份额，PowerFill亦获得了24个国家和地 区的注册批准，体现出REGEN Biotech, I ...